Ritonavir
Ritonavir is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Ritonavir; Generic name: RITONAVIR; Drug class: Cytochrome P450 3A Inhibitor [EPC].
| Brand name | Ritonavir |
|---|---|
| Generic name | RITONAVIR |
| Drug class | Cytochrome P450 3A Inhibitor [EPC] |
| Manufacturer | Aurobindo Pharma Limited |
| Used for | 1 INDICATIONS AND USAGE Ritonavir tablets are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Ritonavir tablets are HIV protease inhibitors indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection ( 1 ) |
| Dosage | 2 DOSAGE AND ADMINISTRATION Adult patients: 600 mg twice-day with meals ( 2.3 ) Pediatrics patients: The recommended twice daily dose for children greater than one month of age is based on body surface area and should not exceed 600 mg twice daily with meals ( 2.4 ) Ritonavir oral solution should not be administered to neonates before a postmenstrual age (first day of the mother’s last menstrual period to birth plus the time elapsed after birth) of 44 weeks has been attained ( 2.4 , 5.2 ) Ritona |
| Warnings | WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS Co-administration of ritonavir with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of ritonavir on the hepatic metabolism of certain drugs. Review medications taken by patients prior to prescribing ritonavir or when prescribing other medications to p |
| Active ingredient(s) | RITONAVIR |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11f757f1-cf48-47a8-925e-918359cbd2d4 |